Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16327095 | 0.87 | CHRNA7 (0.43) | CHRNA7HTR2AHRH1TDP1TSHR | |
| SCHEMBL3028964 | 0.79 | TAAR1 (0.43) | HTR2AHRH1TDP1TSHRSLC6A2 | |
| SCHEMBL8754723 | 0.78 | HTR2A (0.70) | HTR2AHRH1TDP1TSHRALDH1A1 | |
| SCHEMBL10429837 | 0.77 | HTR2A (0.47) | CHRNA7HTR2AHRH1 | |
| SCHEMBL16327150 | 0.77 | AOC3 (0.48) | CHRNA7HTR2AHRH1ALDH1A1SLC6A2 | |
| SCHEMBL26921899 | 0.77 | CHRNA7 (0.46) | CHRNA7HTR2AHRH1TDP1TSHR | |
| SCHEMBL12891079 | 0.76 | KCNH2 (0.43) | HTR2AHRH1TDP1TSHRALDH1A1 | |
| SCHEMBL3989199 | 0.72 | ADRA2A (0.48) | CHRNA7TDP1ALDH1A1ACHESLC6A2 | |
| SCHEMBL4415127 | 0.71 | ACHE (0.43) | CHRNA7ALDH1A1ACHESLC6A2SLC6A4 | |
| SCHEMBL16151931 | 0.71 | ACHE (0.43) | CHRNA7ALDH1A1ACHESLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879808-B2 | potent activity against resistant pneumococci; for treating domestic fowl | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20100210570-A1 | LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2010-08-19 | — | — | US | disclosed |
| US-4791063-A | REMOVAL OF CONTAMINANTS FROM BIOLOGICAL FLUIDS | CUNO INCORPORATED (US) | 1988-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210570-A1 | LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | LAS1L, LCLAT1, LYPLA1 | CHRNA7 4720/4885HTR2A 3515/4885HRH1 1405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.